The slight revenue decline and net loss may concern investors, but the improved gross margin and strategic acquisition of Elevated Softgels could signal potential for future growth. The acquisition is particularly significant as it aims to enhance CV Sciences' production capabilities and market speed for new products, which could improve long-term profitability and shareholder value. However, the current financial performance and the stock trading lower suggest a neutral short-term impact.